Literature DB >> 21901254

Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells.

Cho-Yun Chung1, Young-Lan Park, Young-A Song, Eun Myung, Kyu-Yeol Kim, Gi-Hoon Lee, Ho-Seok Ki, Kang-Jin Park, Sung-Bum Cho, Wan-Sik Lee, Young-Do Jung, Kyung-Keun Kim, Young-Eun Joo.   

Abstract

BACKGROUND/AIMS: Altered Recepteur d'Origine nantais (RON) expression transduces signals inducting invasive growth phenotype that includes cell proliferation, migration, matrix invasion, and protection of apoptosis in human cancer cells. The aims of the current study were to evaluate whether RON affects tumor cell behavior and cellular signaling pathways including activator protein-1 (AP-1) and Akt/forkhead box O (FoxO) in human colorectal cancer cells.
METHODS: To study the biological role of RON on tumor cell behavior and cellular signaling pathways in human colorectal cancer, we used small interfering RNA (siRNA) to knockdown RON gene expression in human colorectal cancer cell line, DKO-1.
RESULTS: Knockdown of RON diminished migration, invasion, and proliferation of human colorectal cancer cells. Knockdown of RON decreased AP-1 transcriptional activity and expression of AP-1 target genes. Knockdown of RON activated cleaved caspase-3, -7, -9, and PARP, and down-regulated the expression of Mcl-1, survivin and XIAP, leading to induction of apoptosis. Knockdown of RON induced cell cycle arrest in the G2/M phase of cancer cells by an increase of p27 and a decrease of cyclin D3. Knockdown of RON inhibited the phosphorylation of Akt/FoxO signaling proteins such as Ser473 and Thr308 of Akt and FoxO1/3a.
CONCLUSIONS: These results indicate that knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901254     DOI: 10.1007/s10620-011-1892-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

Review 1.  The "O" class: crafting clinical care with FoxO transcription factors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 2.  Social controls on cell survival and cell death.

Authors:  M C Raff
Journal:  Nature       Date:  1992-04-02       Impact factor: 49.962

Review 3.  Adding more content to screening: reactivation of FOXO as a therapeutic strategy.

Authors:  Fabian Zanella; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-10       Impact factor: 3.405

Review 4.  Colon carcinogenesis: Learning from NF-kappaB and AP-1.

Authors:  Aristides G Vaiopoulos; Katerina K Papachroni; Athanasios G Papavassiliou
Journal:  Int J Biochem Cell Biol       Date:  2010-03-27       Impact factor: 5.085

5.  Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.

Authors:  Zhuzhu Li; Hangping Yao; Sunny Guin; Snehal S Padhye; Yong-Qing Zhou; Ming-Hai Wang
Journal:  Int J Oncol       Date:  2010-08       Impact factor: 5.650

Review 6.  Cell metabolism: an essential link between cell growth and apoptosis.

Authors:  Emily F Mason; Jeffrey C Rathmell
Journal:  Biochim Biophys Acta       Date:  2010-09-08

Review 7.  Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.

Authors:  Neil Johnson; Geoffrey I Shapiro
Journal:  Expert Opin Ther Targets       Date:  2010-11       Impact factor: 6.902

8.  The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.

Authors:  Piera Maggiora; Annalisa Lorenzato; Stefano Fracchioli; Barbara Costa; Massimo Castagnaro; Riccardo Arisio; Dionyssios Katsaros; Marco Massobrio; Paolo M Comoglio; Maria Flavia Di Renzo
Journal:  Exp Cell Res       Date:  2003-08-15       Impact factor: 3.905

Review 9.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

Authors:  Ralph J DeBerardinis; Julian J Lum; Georgia Hatzivassiliou; Craig B Thompson
Journal:  Cell Metab       Date:  2008-01       Impact factor: 27.287

10.  FOXO transcription factors: key regulators of cell fate.

Authors:  E W-F Lam; R E Francis; M Petkovic
Journal:  Biochem Soc Trans       Date:  2006-11       Impact factor: 5.407

View more
  11 in total

1.  A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Future Neurol       Date:  2012-11

Review 2.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

3.  RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.

Authors:  Jun-Feng Chen; Bi-Xia Yu; Liang Ma; Xiu-Yi Lv; Jun-Hui Jiang; Qi Ma
Journal:  Oncol Lett       Date:  2018-02-28       Impact factor: 2.967

Review 4.  Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Prog Neurobiol       Date:  2012-08-15       Impact factor: 11.685

Review 5.  Targeting disease through novel pathways of apoptosis and autophagy.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang
Journal:  Expert Opin Ther Targets       Date:  2012-08-27       Impact factor: 6.902

6.  The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.

Authors:  Xiangmin Tong; Xuewu Zhang; Jian Fan; Yin Tong; Shuangshuang Li; Jie Jin; Hangping Yao
Journal:  Cancer Biol Ther       Date:  2013-01-29       Impact factor: 4.742

Review 7.  FOXO1: Another avenue for treating digestive malignancy?

Authors:  Feiyu Shi; Tian Li; Zhi Liu; Kai Qu; Chengxin Shi; Yaguang Li; Qian Qin; Liang Cheng; Xin Jin; Tianyu Yu; Wencheng Di; Jianwen Que; Hongping Xia; Junjun She
Journal:  Semin Cancer Biol       Date:  2017-09-28       Impact factor: 15.707

8.  PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

9.  Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.

Authors:  Jun-Feng Chen; Bi-Xia Yu; Rui Yu; Liang Ma; Xiu-Yi Lv; Yue Cheng; Qi Ma
Journal:  Oncol Rep       Date:  2017-01-05       Impact factor: 3.906

10.  Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR.

Authors:  Kenneth Maiese
Journal:  Indian J Med Res       Date:  2013-02       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.